Fall 2017-Spring 2018 Schedule

Location: Simches Research Center, Room 3110
Time: 12:00–1:00 PM
Intended Audience: Internal MGH Faculty and Staff

The Massachusetts General Hospital Grand Rounds program has emerged as a premiere oncology conference in Boston. This program provides an opportunity for Mass General professional staff and fellows to learn from national and international leaders and innovators in cancer treatment and research.

Grand Rounds offers CME credit, and is structured as a 45 minute lecture followed by 15 minutes of discussion and interaction. Please see below to view the weekly topics and presenters.

October 2017

  • ASCO Update

    October 5, 2017

    Ryan Nipp, MD, MPH
    Zofia Piotrowska, MD
    Laura Spring, MD
    Justin Gainor, MD

  • Molecular Diversity of Human Breast Cancer: Biologic and Therapeutic Implications

    October 12, 2017

    Dennis Slamon, MD, PhD
    UCLA Department of Medicine
    Director of Clinical/Translational Research
    Director of the Revlon/UCLA Women's Cancer Research Program
    Jonsson Comprehensive Cancer Center
    Professor of Medicine
    Chief of the Division of Hematology/Oncology

  • Clinical Pathologic Conference: A 36-Year Old Pregnant Woman with a Recent Diagnosis of Colon Cancer

    October 19, 2017

    Janet E. Murphy, MD, MPH
    Hematology/Oncology, MGH

    Jeffrey Clark, MD
    Hematology/Oncology, MGH

    Laura E. Riley, MD

    Kimberly Shampain, MD
    Radiology, MGH

    Kristin M. Basnet, MD
    Pathology, MGH

  • The Role of Molecular Biology in Optimal Treatment Selection for Breast Cancer

    October 26, 2017

    Laura J. van’t Veer, PhD
    University of California, San Francisco (UCSF)
    Professor of Laboratory Medicine at the University of California, San Francisco
    Program Leader of the Breast Oncology Program and Director of Applied Genomics
    with the UCSF Helen Diller Family Comprehensive Cancer Center

November 2017

  • Targeting the vulnerabilities of sarcomas: from oncogenic transcription to telomere recombination

    November 9, 2017

    Lee Zou, PhD
    Miguel Rivera, MD
    Greg Cote, MD, MPH
    Mass General Cancer Center

  • Coding and non-coding drivers in cancer: from primary to resistant tumors

    November 16, 2017

    Gad Getz, PhD
    Associate Professor of Pathology, Harvard Medical School
    Assistant Pathologist, Massachusetts General Hospital
    Director of Bioinformatics, Massachusetts General Hospital Cancer Center and Department of Pathology
    Paul C. Zamecnik Chair of Oncology, Massachusetts General Hospital Cancer Center
    Director, Cancer Genome Computational Analysis and Associate Member, Broad Institute
    Member, Blue Ribbon Panel, Co-chair of Enhanced Data Sharing working group

  • Translational studies in renal cell carcinoma

    November 30, 2017

    W. Kimryn (Kim) Rathmell, MD, PhD
    Director, Division of Hematology/Oncology
    Cornelius A. Craig Professor of Medicine
    Professor of Clinical Medicine and Cancer Biology

December 2017

  • Identification of Metabolic Dependencies in Pancreatic Cancer

    December 7, 2017

    Alec Kimmelman, MD, PhD
    NYU Langone Health
    Anita Steckler & Joseph Steckler Professor Chairman
    Department of Radiation Oncology
    Laura and Isaac Perlmutter Cancer Center

  • Charting the epigenomic landscape of prostate cancer

    December 14, 2017

    Matthew Freedman, MD
    Dana Farber Cancer Institute
    Associate Physician, Medical Oncology Service

January 2018

  • ASH Update

    January 11, 2018

    Andrew Brunner, MD
    Jacob Soumerai, MD
    Andrew Branagan, MD
    Annemarie Fogerty, MD
    Mass General Cancer Center

  • Hormone Resistant Breast Cancer: ER Reactivation, Reprogramming, and Silencing

    January 18, 2018

    Sarat Chandarlapaty, MD, PhD
    Assistant Member – Human Oncology and Pathogenesis Program
    Memorial Sloan Kettering Cancer Center

  • Thrombopoietin and its receptor in Normal and Neoplastic Hematopoiesis

    January 25, 2018

    Kenneth Kaushansky, MD, MACP
    Stony Brook University
    Senior Vice President, Health Sciences, and Dean, School of Medicine

February 2018

  • The Role of Cell of Origin & Cancer Stem Cells in GBM Phenotype

    February 1, 2018

    Luis F. Parada, PhD
    Memorial Sloan Kettering Cancer Center
    Director, Brain Tumor Center
    Albert C. Foster Chair
    American Cancer Society Research Professor

  • Preclinical Models for Testing of Targeted and Immune Therapies

    February 8, 2018

    Kwok-Kin Wong
    NYU Langone Health

  • Transforming Pancreatic Cancer into an Immunologic Disease

    February 15, 2018

    Elizabeth Jaffee, MD
    Johns Hopkins Medicine
    Deputy Director, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Professor of Oncology

March 2018

  • MSK-IMPACT at 25,000 Cases: Routinizing Clinical Cancer Genomics

    March 1, 2018

    MSK-IMPACT at 25,000 Cases: Routinizing Clinical Cancer Genomics to Enable Broad and Narrow Advances in Precision

    Marc Ladanyi, MD
    Chief, Molecular Diagnostics Service
    Member, Human Oncology and Pathogenesis Program
    Memorial Sloan Kettering Cancer Center

  • Clinical Pathologic Conference: A 64-year-old man with shortness of breath, cough, and hypoxemia

    March 8, 2018

    Jonathan England, MD
    Massachusetts General Hospital

    Florian Fintelmann, MD
    Massachusetts General Hospital

    Michael Mansour, MD, PhD
    Massachusetts General Hospital

    Kerry Reynolds, MD
    Massachusetts General Hospital Cancer Center

    Ryan Sullivan, MD
    Massachusetts General Hospital Cancer Center

  • A New Autophagy Target for Drug Development in Cancer

    March 15, 2018

    Ravi Amaravadi, MD
    Associate Professor of Medicine at the Hospital of the University of Pennsylvania
    Attending Physician , Hospital of the University of Pennsylvania
    Member, Institute of Translational Medicine and Therapeutics
    Member, Abramson Cancer Center
    Member, University of Pennsylvania GI Center for Molecular Studies of Digestive and Liver Diseases
    Co-Leader Cancer Therapeutics Program , Abramson Cancer Center, University of Pennsylvania

  • A Connecticut Yankee in King Arthur’s Court

    Tales of a Medical Oncologist’s Journey through the Land of Localized Bladder Cancer Drug Development

    March 22, 2018

    Noah Hahn, MD
    Associate Professor, Departments of Oncology and Urology
    Director, Medical Oncology Bladder Cancer Program
    Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center
    The James Buchanan Brady Urological Institute
    Johns Hopkins Greenberg Bladder Cancer Institute
    Baltimore, Maryland

April 2018

  • Head and Neck Cancer Illustrates How Immunotherapy is Transforming Oncology

    April 5, 2018

    Ezra Cohen, MD
    UC San Diego Health
    Associate Director, Moores Cancer Center
    Professor of Medicine

  • Targeting Micro-RNAs in Leukemia Stem Cells; From the Bench to the Clinic

    April 12, 2018

    Guido Marcucci, MD
    City of Hope
    Director, Gehr Family Center for Leukemia Research
    Professor, Department of Hematologic Malignancies Translational Science
    Professor, Department of Hematology & Hematopoietic Cell Transplantation

  • The Science of Surviving Cancer – Lessons Learned from our Cancer Survivors

    April 26, 2018

    Smita Bhatia, MD, PhD
    Director, Institute for Cancer Outcomes and Survivorship,
    School of Medicine, University of Alabama at Birmingham

May 2018

  • Immunotherapy Strategies of Gastrointestinal Cancers

    May 3, 2018

    Dung Thi Le, MD
    Johns Hopkins Medicine
    Associate Professor of Oncology

  • Cancer Vaccines in the Era of Immuno-Oncology

    May 10, 2018

    Nora Disis, MD
    University of Washington Medicine
    Director, Tumor Vaccine Medical Oncology
    Department of Medicine
    Division of Oncology

  • Clinical Pathologic Conference: A 52-Year-Old Man Presenting with a Left Breast Mass

    May 17, 2018

    Kristen Basnet, MD
    Massachusetts General Hospital

    Steven Isakoff, MD, PhD
    Massachusetts General Hospital Cancer Center

    Constance Lehman, MD, PhD
    Massachusetts General Hospital

    Douglas Micalizzi, MD, PhD
    Brigham and Women’s Hospital

  • New Strategies to Thwart the Evolution of Targeted Cancer Therapy Resistance

    May 24, 2018

    Trever Bivona, MD, PhD
    University of California San Francisco
    Helen Diller Family Comprehensive Cancer Center
    Associate Professor, Hematology and Oncology

  • Is Blood and Marrow Transplantation Becoming Obsolete?

    May 31, 2018

    Steven Devine, MD
    The Ohio State University
    Wexner Medical Center
    Program Director, Blood and Marrow Transplant Program
    Professor of Internal Medicine